Nonagen's Oncuria granted FDA designation

By staff writers

October 1, 2021 -- The U.S. Food and Drug Administration (FDA) has designated the Oncuria noninvasive bladder cancer test from Nonagen Bioscience as a breakthrough device.

The company said Oncuria is capable of predicting how a patient will respond to therapy. The multiplex immunoassay measures 10 protein biomarkers in a single voided urine sample.

Copyright © 2021

Last Updated ls 10/1/2021 2:48:02 PM